TheStreet's Jim Cramer says investors need to see money come back to high-growth names, which have seen a shrinking price-to-earnings multiple. Celgene has been in a decline but the company could have $15-$16 earnings power in a couple of years, says Cramer, and it is cheaper than Merck and Pfizer. Cramer is also watching, which has seen a shrinking multiple since it reported a great quarter. If Celgene and Salesforce turn around, money will come back to high-growth from value names.

At the time of publication, Cramer was long ___.

If you liked this article you might like

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks